Bolt Biotherapeutics vs Xenetic Biosciences
BOLT and XBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BOLT and XBIO compare
Bolt Biotherapeutics is the larger company, worth 3.0 times as much as Xenetic Biosciences ($11.7M against $3.9M).
Bolt Biotherapeutics grew revenue faster over the last twelve months (12.8% versus 3.5% for Xenetic Biosciences).
Xenetic Biosciences keeps more of each dollar of sales as profit, with a net margin of −124% compared with −611% at Bolt Biotherapeutics.
Bolt Biotherapeutics scores higher on the StockData Score (11 against 10 for Xenetic Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BOLT | XBIO |
|---|---|---|
| Size and price | ||
| Market cap | $11.7M | $3.9M |
| Share price | $6.08 | $1.66 |
| Change, 1 year | 29.6% | −37.1% |
| Change, 5 years | −96.5% | −88.8% |
| Beta (5Y) | 0.63 | 0.87 |
| Employees | 23 | 2 |
| StockData Score | ||
| Total score | 11 (better) | 10 |
| Valuation score | 3 | 3 |
| Growth score | 2 (better) | 1 |
| Performance score | 1 | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.5× | 1.3× (better) |
| P/B | 0.9× | 0.9× (better) |
| Fair value | $8.70 | $3.65 |
| Margin of safety | 30.1% | 54.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 12.8% (better) | 3.5% |
| Revenue growth, 5Y average | 102% (better) | 46.8% |
| Profitability | ||
| Operating margin | −655% | −130% (better) |
| Net margin | −611% | −124% (better) |
| Return on equity | −112% | −87.5% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 2.61 | 3.15 (better) |
| Altman Z-score | −18.28 (better) | −44.51 |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Buyback yield | −0.26% | – |
| Shareholder yield | −0.26% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 31.0% | 6.5% |
| Held by insiders | 12.2% | 12.2% |
| Insider net buying, 12 months | $196K | – |
| Short interest, % of float | 2.8% | 1.8% |
Go deeper
- BOLT stock overview
- BOLT income statement
- BOLT valuation and score
- XBIO stock overview
- XBIO income statement
- XBIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.